Kura Oncology closes $77.1M stock offering
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Insight Weekly: Renewables lead capacity additions; bank mergers of equals up; nickel IPOs surge
Insight Weekly: Utilities face headwinds; S&P 500 dividend hikes likely; dollar poised for rally
Kura Oncology Inc. closed its public offering to raise about $77.1 million in gross proceeds.
The San Diego-based biopharmaceutical company issued 4.6 million common shares at $16.75 apiece, which included 600,000 shares bought by the underwriters after they exercised their option in full.
Leerink Partners acted as sole book-running manager for the offering.
